造血干细胞移植术后儿童感染新型冠状病毒Omicron的临床特征分析

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1856 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the difference of clinical features between children who received hematopoietic stem cell transplantation and normal children without underlying diseases infected with Omicron variant of SARS-CoV-2(hereinafter referred to as Omicron). Methods Clinical data on Omicron-infected children from 2022-12-01 to 2023-1-20 were analyzed retrospectively. Eighty-one children who had received hematopoietic stem cell transplants were included in the transplant group, and 507 normal children without underlying medical conditions were included in the normal group. The differences in clinical characteristics between the two groups were compared. Results There were no significant differences in age or gender between the transplant group and the normal group. The main symptom of Omicron infection in both groups was fever, 64 cases (79.0%) in the transplantation group compared with 389 cases (76.7%) in the normal group. The second most common symptom was cough, 57 cases (70.4%) in the transplantation group were compared with 306 cases (60.4%) in the normal group. There was no statistical significance in fever and cough symptoms between the two groups. At the same time, there were no significant differences between the transplantation group and the normal group in high fever (34.6% vs 36.7%), dyspnea (4.9% vs 2.8%), nasal congestion (43.2% vs 46.5%), and sore throat (35.8% vs 28.4%). In addition, gastrointestinal discomfort (50.6% vs 27.2%), sepsis (3.7% vs 0.2%), respiratory support (3.7% vs 0%), and total disease duration over 2 weeks (43.2% vs 10.1%) in the transplant group were significantly higher than those in the normal group. Conclusion Omicron infection was mainly mild in both the transplant and normal groups, but the incidence of moderate to severe infection was higher in the transplant group than in the normal group, and the duration of the disease was longer. Infected children following hematopoietic stem cell transplantation should still be actively prevented from serious infections and serious adverse events.

Key words： children hematopoietic stem cell transplantation SARS-CoV-2 Omicron clinical features

Received: 17 February 2023

PACS:

R373.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Shuai
	ZENG Minhui
	HE Jing
	TIAN Xin
	CHEN Keke
	HE Xiangling

Cite this article:

WU Shuai,ZENG Minhui,HE Jing等. Clinical features of SARS-CoV-2 Omicron variant infection in children after hematopoietic stem cell transplantation[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 71-74.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2023/V20/I3/71

[1] Ai J, Zhang H, Zhang Y, et al.Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11(1): 337-343.
[2] 张苡菲, 梁世山, 吴沛霖, 等.201例儿童新型冠状病毒Omicron变异株感染的临床特征分析[J]. 中国当代儿科杂志, 2023, 25(1): 5-10.
[3] Ullrich F, Hanoun C, Turki AT, et al.Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variant[J]. Eur J Haematol, 2022, 09(4): 364-372.
[4] 中华人民共和国国家卫生健康委员会医政医管局. 关于印发新型冠状病毒感染诊疗方案 (试行第十版) 的通知 (国卫办医急函〔2023〕4号)[EB/OL]. https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm
[5] Sarkar A, Omar S, Alshareef A, et al.The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review[J]. Hum Vaccin Immunother, 2023, 19(1): 2212568
[6] Harrison AG, Lin T, Wang P.Mechanisms of SARS-CoV-2 Transmission and Pathogenesis[J]. Trends Immunol, 2020, 41(12): 1100-1115.
[7] Perlman S, Netland J.Coronaviruses post-SARS: update on replication and pathogenesis[J]. Nat Rev Microbiol, 2009, 7(6): 439-450.
[8] WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern[EB/OL]. Available at: https: //www. who. int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529) -sars-cov-2-variant-of-concern.
[9] Guo Y, Han J, Zhang Y, et al.SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance[J]. Front Immunol, 2022, 29(13): 877101.
[10] Papanikolaou V, Chrysovergis A, Ragos V, et al.From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants[J]. Gene, 2022, 10(814): 146134.
[11] Fantini J, Yahi N, Colson P, et al.The puzzling mutational landscape of the SARS-2-variant Omicron[J]. J Med Virol, 2022, 94(5): 2019-2025.
[12] Ali EAH, Khamees I, Alshurafa A, et al.Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience[J]. Oncology, 2022, 100(8): 460-466.
[13] Ali EA, Khamees I, Abu-Tineh M, et al.SARS-CoV-2 Omicron Variant in Patients With Chronic Myeloid Leukemia: A Retrospective Study[J]. Cureus, 2022, 14(4): 23863.
[14] Ali EA, Alamin MA, Abu-Tineh M, et al.A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia[J]. Cureus, 2022, 14(5): 25196.
[15] Malahe SRK, Hoek RAS, Dalm VASH, et al.Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study[J]. Clin Infect Dis, 2022, 76(3): 172-178
[16] Nevejan L, Ombelet S, Laenen L, et al.Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts[J]. Viruses, 2022, 14(12): 2736.
[17] Cauchi JP, Dziugyte A, Borg ML, et al.Hybrid immunity and protection against infection during the Omicron wave in Malta[J]. Emerg Microbes Infect, 2023, 12(1): 2156814.
[18] Xu H, Li H, You H, et al.Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China[J]. Emerg Microbes Infect, 2023, 12(1): 2149935.
[19] Blennow O, Salmanton-García J, Nowak P, et al.Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report[J]. Am J Hematol, 2022, 97(8): 312-317.